BioWorld Asia

Nov. 14, 2007

Antisense Pharma Gets $39.5M For Antisense Glioma Product

Antisense Pharma GmbH raised €27 million (US$39.5 million) in a third investment round funded solely by MIG AG, which also was the only investor in its €18 million funding round two years ago. (BioWorld International) Read More

Acambis Partners West Nile Vaccine In $80M Sanofi Deal

Novel Obesity Gene Plays A Role In Modifying DNA

Actelion Advances Clazosentan Into Phase III Vasospasm Study

Peptech Reinvents Itself As Arana, Shifts To Antibodies

Cerep Sells Hesperion To CRO Averion In €25M Deal

No Abstract Read More

Activists Strike At European Industry's Lobbying Power

Other News To Note

LSD Deal Brings Amicus $50M Now, $390M Later

As Big Pharma Model Falters, Biotech Rides To The Rescue

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...